Dr. Dean J. Burkin

University of Nevada School of Medicine,USA

Email: [email protected]

Qualifications

1994 Ph.D., Biochemistry , University of Colorado, USA

1986 B.Sc., Developmental Biology, Victoria University, New Zealand

Publications (Selected)

1. Barraza-Flores, P., Bates, C. R., & Oliveira-Santos, A. (2020). Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics. Frontiers in Molecular Neuroscience, 13, 1.
2. Barraza-Flores, P., Bukovec, K. E., Dagda, M., et al. (2020). Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy. Human Molecular Genetics, 29(13), 2162-2170.
3. Barraza-Flores, P., Fontelonga, T. M., Wuebbles, R. D., et al. (2019). Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy. Human Molecular Genetics, 28(16), 2686-2695.
4. Barraza-Flores, P., Hermann, H. J., Bates, C. R., et al. (2020). Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD. Skeletal Muscle, 10(1), 18.
5. Bugiardini, E., Nunes, A. M., Oliveira-Santos, A., et al. (2022). Integrin α7 Mutations Are Associated With Adult-Onset Cardiac Dysfunction in Humans and Mice. Journal of the American Heart Association, 11(23), e026494.
6. Bugiardini, E., Phadke, R., Maas, R., et al. (2018). Recessive loss-of-function mutations in ITGA7 cause cardiac arrhythmia with or without structural cardiomyopathy and respiratory muscle weakness. Neuromuscular Disorders, 28(S2), S131.
7. Bugiardini, E., Phadke, R., Maas, R., et al. (2019). Recessive loss-of-function mutations in ITGA7 cause cardiac arrhythmia with or without structural cardiomyopathy and respiratory muscle weakness. Neuropathology and Applied Neurobiology, 45(S1), 35.
8. Bugiardini, E., Phadke, R., Pittman, A. M., et al. (2017). ITGA7 MUTATIONS CAUSE CARDIAC ARRHYTHMIA AND RESPIRATORY MUSCLE WEAKNESS. Muscle & Nerve, 56(S1), S1.
9. Fontelonga, T. M., Jordan, B., Nunes, A. M., et al. (2019). Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy. Human Molecular Genetics, 28(13), 2120-2132.
10. Garg, K., Mahmassani, Z. S., Dvoretskiy, S., et al. (2021). Laminin-111 Improves the Anabolic Response to Mechanical Load in Aged Skeletal Muscle. Journals of Gerontology Series A-Biological Sciences and Medical Sciences, 76(4), 586-590.
11. Hermann, H., Wuebbles, R. D., & Burkin, D. J. (2023). A gene therapy approach for the treatment of limb-girdle muscular dystrophy 2C/R5. Molecular Therapy-Methods & Clinical Development, 29, 160-161.
12. Hermann, H. J., McDermott, S., & Burkin, D. J. (2026). A molecular makeover of lamininα4with linker proteins to mimic the function of laminin-α2 for the treatment of LAMA2-CMD. Molecular Therapy, 34(5), 2544-2546.
13. Hermann, H. J., Wuebbles, R. D., Dagda, M., et al. (2025). Spatial proteomics reveals recombinant human laminin-111 restores adhesion signaling to laminin-α2-deficient muscle. JCI Insight, 10(22), e194581.
14. Jones, T. I., Chew, G. L., Barraza-Flores, P., et al. (2020). Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity. Skeletal Muscle, 10(1), 8.
15. Lewon, M., Peters, C. M., Van Ry, P. M., et al. (2017). Evaluation of the behavioral characteristics of the mdx mouse model of duchenne muscular dystrophy through operant conditioning procedures. Behavioural Processes, 142, 8-20.
16. Oliveira-Santos, A., Dagda, M., & Burkin, D. J. (2022). Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy. Human Molecular Genetics, 31(14), 2358-2369.
17. Oliveira-Santos, A., Dagda, M., Wittmann, J., et al. (2023). Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy. Disease Models & Mechanisms, 16(6), dmm049916.
18. Sarathy, A., Wuebbles, R. D., Fontelonga, T. M., et al. (2017). SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy, 25(6), 1395-1407.
19. Tannous, C., Deloux, R., Karoui, A., et al. (2021). NMRK2 Gene Is Upregulated in Dilated Cardiomyopathy and Required for Cardiac Function and NAD Levels during Aging. International Journal of Molecular Sciences, 22(7), 3534.
20. Van Ry, P. M., Fontelonga, T. M., Barraza-Flores, P., et al. (2017). ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies. Comprehensive Physiology, 7(4), 1519-1536.
21. Wuebbles, R. D., & Burkin, D. J. (2020). A retooled drug that restores ionic balance and cardiac function in dystrophin deficient hearts. International Journal of Cardiology, 319, 115-116.
22. Wuebbles, R. D., Cruz, V., Van Ry, P., et al. (2019). Human Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy-Methods & Clinical Development, 13, 145-153.

Profile Details
https://med.unr.edu/directory/research-labs/dean-burkin-lab
https://scholar.google.com/citations?user=aopw69YAAAAJ&hl=en
https://www.researchgate.net/scientific-contributions/Dean-J-Burkin-54216154

WOS ResearcherID: ABC-4395-2021